Study Title: A Phase I/II Trial of the Pharmacokinetics, Tolerability, and Safety of Once-Weekly Rifapentine and Isoniazid in HIV-1-infected and HIV-1-uninfected Pregnant and Postpartum Women with Latent Tuberculosis Infection
Protocol summary:
IMPAACT 2001 is a Phase I/II, prospective, open-label, multi-center study of HIV-1-infected and HIV-1-uninfected pregnant and postpartum women with latent tuberculosis (TB) infection. The study is designed to describe the pharmacokinetics and safety of 12 once-weekly doses of rifapentine (RPT) and isoniazid (INH) in pregnant and postpartum women with latent TB and inform the practice on usage of this regimen in the second and third trimesters of pregnancy.
Location: HFC CRS
IMPAACT
Current Study
Comments are closed.